Daily non-political popular news in brief.

Preliminary results suggest Certolizumab Pegol is effective in reducing signs and symptoms

Fifty-nine percent of patients receiving certolizumab pegol 200mg plus methotrexate, and 61 percent of patients receiving certolizumab pegol 400mg plus methotrexate every two weeks achieved a 20 percent improvement in symptoms (known as an American College of Rheumatology 20 Response) after 24 weeks' treatment, according to a study presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain. Only 14 percent of patients receiving methotrexate alone achieved an ACR20 response over the same period, highlighting the superiority of the treatment combination at both doses of certolizumab pegol in patients refractory to methotrexate.

Read more »

Keywords: preliminary, results, suggest, certolizumab, pegol, effective, reducing, signs, symptoms, result, sign, symptom

« Previous | Next »

Similar news on "Preliminary results suggest Certolizumab Pegol is effective in reducing signs and symptoms":

1. Exercise can cut coronary artery disease risk for some with MS
   04-30-2007 · EurekAlert!
   Results of a new study suggest that people with mild to moderate MS are capable of improving their aerobic fitness levels similar to their non-MS counterparts. While physical inactivity may predispose MS patients to have increased coronary artery disease risk, MS-related symptoms don't preclude this group from potentially reducing their risk factors through exercise.
   Similar news · Read more »
   
2. Jefferson neuroscientists show anti-inflammation molecule helps fight MS-like disease
   11-11-2007 · EurekAlert!
   An immune system messenger molecule that normally helps quiet inflammation could be an effective tool against multiple sclerosis. Neurology researchers at Jefferson Medical College have found that the protein interkeukin-27 (IL-27) helped block the onset or reverse symptoms in animals with an MS-like disease. The results suggest that IL-27 may someday be part of a therapy to temper over-active immune responses, which are thought to be at the heart of MS.
   Similar news · Read more »
   
3. DAYTRANA (methylphenidate transdermal system) provides individualized ADHD symptom management
   10-27-2006 · EurekAlert!
   Shire's Attention Deficit Hyperactivity Disorder patch, DAYTRANA tm (methylphenidate transdermal system) has significant efficacy in reducing the symptoms of ADHD in children aged 6 to 12 years, even when removed earlier than the recommended nine hours. The ability to remove the patch earlier allows physicians the opportunity to manage potential late-day side effects, such as lack of appetite or difficulty sleeping, according to phase 3b trial results reported at a scientific child and adolescent psychiatry meeting in San Diego.
   Similar news · Read more »
   
4. New neurons could act to alleviate epilepsy
   12-20-2006 · EurekAlert!
   The new neurons generated as a result of neural damage due to epilepsy show a reduced excitability that could alleviate the disorder, researchers have found. The researchers said their results suggest that therapies for epilepsy aimed at inducing neurogenesis could prove effective in alleviating the disorder.
   Similar news · Read more »
   
5. Research shows new therapy is effective for patients with Crohn's disease
   07-18-2007 · EurekAlert!
   Mayo Clinic researchers have found that Certolizumab pegol is an effective treatment for adults with Crohn's disease, according to two new studies. These findings were published in today's issue of the New England Journal of Medicine. Certolizumab pegol blocks tumor necrosis factor, an important cause of inflammation in Crohn's disease
   Similar news · Read more »
   
6. Undiagnosed OSA patients have altered cardiovascular responses during exercise recovery
   01-01-2008 · EurekAlert!
   People with untreated obstructive sleep apnea have altered cardiovascular responses during recovery from maximal exercise. These results suggest an imbalance in the autonomic control of heart rate during recovery, and may be an early clinical sign of the progression of OSA.
   Similar news · Read more »
   
7. Breast cancer survivors optimistic, yet lack critical information on reducing recurrence
   09-25-2007 · EurekAlert!
   The majority of breast cancer survivors consider themselves stronger after having the disease, according to new survey results released today. However, the data also suggest women's knowledge about actions they can take to lessen the likelihood of recurrence is surprisingly low.
   Similar news · Read more »
   
8. Stroke Symptoms Common Among General Population
   10-12-2006 · ScienceDaily
   As many as 18 percent of adults who have no history of stroke report having had at least one symptom of stroke, according to results of a large national study published in the October 9 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
   Similar news · Read more »
   
9. Tamiflu Significantly Reduces The Risk Of Death From Influenza
   10-02-2006 · ScienceDaily
   Tamiflu (oseltamivir), is effective in reducing the risk of death associated with seasonal influenza in severely ill patients, according to new data. Treatment of infected adults was associated with a 71 percent reduction in mortality. These results demonstrate the importance of the role of antivirals in the management of seasonal influenza and highlights the seriousness and risk of mortality associated with it.
   Similar news · Read more »
   
10. HALT study: Black cohosh no better than placebo for hot flashes
    12-18-2006 · EurekAlert!
    The results of the HALT study, a federally funded study to examine whether black cohosh is an effective treatment for hot flashes and night sweats -- common symptoms of menopause -- found that black cohosh was no better than a dummy pill. The frequency and severity of symptoms declined by about 30 percent over 12 months regardless of whether women were taking black cohosh or placebo.
    Similar news · Read more »